Autolus Therapeutics (AUTL) Equity Average: 2018-2025
Historic Equity Average for Autolus Therapeutics (AUTL) over the last 6 years, with Sep 2025 value amounting to $306.0 million.
- Autolus Therapeutics' Equity Average fell 39.10% to $306.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $306.0 million, marking a year-over-year decrease of 39.10%. This contributed to the annual value of $269.4 million for FY2024, which is 31.37% up from last year.
- As of Q3 2025, Autolus Therapeutics' Equity Average stood at $306.0 million, which was down 14.72% from $358.8 million recorded in Q2 2025.
- Over the past 5 years, Autolus Therapeutics' Equity Average peaked at $554.9 million during Q2 2024, and registered a low of $146.0 million during Q4 2023.
- Its 3-year average for Equity Average is $345.6 million, with a median of $346.8 million in 2024.
- As far as peak fluctuations go, Autolus Therapeutics' Equity Average surged by 209.70% in 2024, and later crashed by 39.10% in 2025.
- Over the past 5 years, Autolus Therapeutics' Equity Average (Quarterly) stood at $279.0 million in 2021, then dropped by 17.60% to $229.9 million in 2022, then plummeted by 36.50% to $146.0 million in 2023, then soared by 209.70% to $452.1 million in 2024, then slumped by 39.10% to $306.0 million in 2025.
- Its Equity Average stands at $306.0 million for Q3 2025, versus $358.8 million for Q2 2025 and $399.2 million for Q1 2025.